BIO-TECHNE CORP shareholders Q3 2023

BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 517 filers reported holding BIO-TECHNE CORP in Q3 2023. The put-call ratio across all filers is 0.43 and the average weighting 0.2%.

BIO-TECHNE CORP shareholders Q3 2023
NameSharesValueWeighting ↓
Dorsey & Whitney Trust CO LLC 155,984$10,617,8320.92%
ArrowMark Colorado Holdings LLC 1,014,159$69,033,8030.84%
ROWLANDMILLER & PARTNERS.ADV 49,135$3,344,6190.82%
Stephens Investment Management Group LLC 699,276$47,599,7170.78%
Affiance Financial, LLC 22,228$1,513,0600.77%
RIVERBRIDGE PARTNERS LLC 721,831$49,135,0540.71%
SEGALL BRYANT & HAMILL, LLC 869,300$59,173,2810.68%
Sanchez Wealth Management Group 21,733$1,479,3450.60%
Kensington Investment Counsel, LLC 14,050$956,3840.59%
ROBERTS GLORE & CO INC /IL/ 26,108$1,777,1720.59%
Oak Thistle LLC 29,168$1,985,4650.59%
Legal Advantage Investments, Inc. 11,135$757,9590.54%
WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC 2,314,269$157,532,2910.52%
ROYCE & ASSOCIATES LP 674,285$45,898,5800.47%
DUALITY ADVISERS, LP 56,338$3,834,9280.46%
Linden Thomas Advisory Services, LLC 27,542$1,874,7840.42%
SHERBROOKE PARK ADVISERS LLC 18,105$1,232,4070.39%
GraniteShares Advisors LLC 6,107$415,7030.39%
Palisade Asset Management, LLC 46,419$3,159,7410.38%
FRED ALGER MANAGEMENT, LLC 956,078$65,080,2460.37%
About BIO-TECHNE CORP

Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.

Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.

In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.

Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.

Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.

It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.

External links

This page lists BIO-TECHNE CORP's shareholders in Q3 2023. To view BIO-TECHNE CORP's shareholder history, click here.